uniQure N.V.

QURENASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
27.05 USD
↘ 0.70 (2.52%)AT CLOSE (11:59 AM EDT)
27.75
↗ 0.70 (2.59%)
POST MARKET (AS OF 07:56 PM EDT)
Post Market
AS OF 07:56 PM EDT
27.75
↗ 0.70 (2.59%)
🔴Market: CLOSED
Open?$27.40
High?$27.74
Low?$26.37
Prev. Close?$27.75
Volume?1.5M
Avg. Volume?2.0M
VWAP?$26.91
Rel. Volume?0.74x
Bid / Ask
Bid?$23.17 × 100
Ask?$30.68 × 100
Spread?$7.51
Midpoint?$26.93
Valuation & Ratios
Market Cap?1.7B
Shares Out?62.5M
Float?55.9M
Float %?89.4%
P/E Ratio?N/A
P/B Ratio?11.42
EPS?-$3.31
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
221
Market Cap
1.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.uniqure.com
Listed
2014-02-05
Address
PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?10.40Strong
Quick Ratio?10.40Strong
Cash Ratio?2.36Strong
Debt/Equity?0.33Low
ValuationRICHLY VALUED
Score
50/100
P/E?
N/A▾
P/B?
11.42HIGH▾
P/S?
94.29HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
-9.5CHEAP▾
EV/Sales?
89.31HIGH▾
Returns & Efficiency
ROE?
-139.9%WEAK▾
ROA?
-26.8%WEAK▾
Cash Flow & Enterprise
FCF?$-172559000
Enterprise Value?$1.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist